Market research
ICPT Intercept Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 795M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 0.88
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 795M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- 0.0%
- Beta
- 0.88
About
About Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Research context
Intercept Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ICPT discussion.
5 years, 7 months ago
Intercept Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 29.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.
Intercept Pharmaceuticals, Inc's total revenue rose by 16.5% to $83M since the same quarter in the previous year.
Its net income has increased by 46.9% to $-52M since the same quarter in the previous year.
Finally, its free cash flow grew by 70.5% to $-18M since the same quarter in the previous year.
Based on the above factors, Intercept Pharmaceuticals, Inc gets an overall score of 4/5.